title: Monoclonal antibodies in targeted therapy.
abstract: Targeted therapy is a new therapeutic method consisting in the inhibition of specific molecular pathways. In modern therapy, the key role is played by monoclonal antibodies, included in the group of biological agents. The success of molecularly targeted therapy is to define the proper "molecular target", selecting the right drug active against a specific "target" and selecting a group of patients who benefit from treatment. Introduction of targeted therapy resulted in improved results of the treatment of many serious and chronic diseases. In general, targeted molecular therapies have good toxicity profiles, but some patients are exquisitely sensitive to these drugs and can develop particular and severe toxicities. Patient selection and proper monitoring significantly decrease the risk of life-threatening adverse events. Data concerning late side effects are still unavailable because of the short follow-up of molecularly targeted therapy. Currently in the U.S. and Europe there are approximately 31 registered therapeutic monoclonal antibodies, while 160 are subjected to clinical trials. This paper presents an overview of therapeutic monoclonal antibodies currently used in therapy and the present state of knowledge about them.
authors.affiliation: Katedra Technologii i Biotechnologii Środków Leczniczych, Wydział Farmaceutyczny, Uniwersytet Jagielloński-Collegium Medicum w Krakowie, ul. Medyczna 9, 30-68 Kraków, Poland.
authors.forename: Beata
authors.initials: B
authors.lastname: Powroźnik
authors.forename: Paulina
authors.initials: P
authors.lastname: Kubowicz
authors.forename: Elżbieta
authors.initials: E
authors.lastname: Pękala
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001249:Asthma / Q000628:therapy; D001327:Autoimmune Diseases / Q000628:therapy; D003424:Crohn Disease / Q000628:therapy; D005060:Europe; D019337:Hematologic Neoplasms / Q000628:therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007414:Intestinal Neoplasms / Q000628:therapy; D008268:Macular Degeneration / Q000628:therapy; D058990:Molecular Targeted Therapy / Q000379:methods*; D008991:Monitoring, Physiologic / Q000379:methods; D009103:Multiple Sclerosis / Q000628:therapy; D018579:Patient Selection; D011565:Psoriasis / Q000628:therapy; D016378:Tissue Transplantation / Q000379:methods
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; C026408:anti-IgE antibodies